KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Notes Payables (2019 - 2025)

Historic Notes Payables for BioNTech SE (BNTX) over the last 7 years, with Q3 2025 value amounting to $45.0 million.

  • BioNTech SE's Notes Payables changed N/A to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2023, which is N/A changed from last year.
  • As of Q3 2025, BioNTech SE's Notes Payables stood at $45.0 million.
  • In the past 5 years, BioNTech SE's Notes Payables registered a high of $309.3 million during Q2 2021, and its lowest value of $2.5 million during Q4 2023.
  • Moreover, its 5-year median value for Notes Payables was $174.4 million (2022), whereas its average is $142.6 million.
  • Its Notes Payables has fluctuated over the past 5 years, first crashed by 3888.79% in 2022, then soared by 184494.64% in 2025.
  • Over the past 5 years, BioNTech SE's Notes Payables (Quarter) stood at $196.3 million in 2021, then grew by 21.73% to $239.0 million in 2022, then tumbled by 98.96% to $2.5 million in 2023, then rose by 0.97% to $2.5 million in 2024, then surged by 1701.33% to $45.0 million in 2025.
  • Its Notes Payables was $45.0 million in Q3 2025, compared to $44.7 million in Q2 2025 and $48.6 million in Q1 2025.